BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 19604516)

  • 1. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Wang Y; Zhang Y; Wei Z; Li H; Zhou H; Zhang Z; Zhang Z
    J Neurol Sci; 2009 Oct; 285(1-2):172-7. PubMed ID: 19604516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
    Wang YS; Zhou JP; Wei ZF; Tian QY; Zhou HX; Zhang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1199-202, 1205. PubMed ID: 17715026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
    Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
    Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway.
    Yu S; Zheng W; Xin N; Chi ZH; Wang NQ; Nie YX; Feng WY; Wang ZY
    Rejuvenation Res; 2010 Feb; 13(1):55-64. PubMed ID: 20230279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease.
    Wang W; Shi L; Xie Y; Ma C; Li W; Su X; Huang S; Chen R; Zhu Z; Mao Z; Han Y; Li M
    Neurosci Res; 2004 Feb; 48(2):195-202. PubMed ID: 14741394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Zishenpingchan granule prepared from Chinese medicinal substances on the c-Jun N-terminal protein kinase pathway in mice with Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Ye Q; Yuan X; Zhou J; Yuan C; Yang X
    J Tradit Chin Med; 2017 Apr; 37(2):244-51. PubMed ID: 29960635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Doo AR; Kim ST; Kim SN; Moon W; Yin CS; Chae Y; Park HK; Lee H; Park HJ
    Neurol Res; 2010 Feb; 32 Suppl 1():88-91. PubMed ID: 20034453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo.
    Saporito MS; Thomas BA; Scott RW
    J Neurochem; 2000 Sep; 75(3):1200-8. PubMed ID: 10936203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside in the MPTP-induced mouse model of Parkinson's disease: Involvement of reactive oxygen species-mediated JNK, P38 and mitochondrial pathways.
    He H; Wang S; Tian J; Chen L; Zhang W; Zhao J; Tang H; Zhang X; Chen J
    Eur J Pharmacol; 2015 Nov; 767():175-82. PubMed ID: 26477638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease.
    Huang Q; Du X; He X; Yu Q; Hu K; Breitwieser W; Shen Q; Ma S; Li M
    Exp Neurol; 2016 Mar; 277():296-304. PubMed ID: 26515688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
    Ghosh A; Roy A; Matras J; Brahmachari S; Gendelman HE; Pahan K
    J Neurosci; 2009 Oct; 29(43):13543-56. PubMed ID: 19864567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease.
    Xia XG; Harding T; Weller M; Bieneman A; Uney JB; Schulz JB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10433-8. PubMed ID: 11504916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
    Kubo K; Inada T; Shingu K
    Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
    Pariyar R; Bastola T; Lee DH; Seo J
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
    Willesen MG; Gammeltoft S; Vaudano E
    Ann N Y Acad Sci; 2002 Nov; 973():237-40. PubMed ID: 12485868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
    Hunot S; Vila M; Teismann P; Davis RJ; Hirsch EC; Przedborski S; Rakic P; Flavell RA
    Proc Natl Acad Sci U S A; 2004 Jan; 101(2):665-70. PubMed ID: 14704277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.